Skip to main content
SpringerLink
Log in

Newer Therapeutic Options for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder with variable symptoms and severity that can be difficult to diagnose. Intravenous immunoglobulin, plasma exchange and corticosteroids have all been proven to be beneficial in randomized controlled trials, although the proof for corticosteroids is less clear. Although these treatments are likely to be similar in efficacy, they differ in terms of their cost, availability and adverse effects. These characteristics should be taken into account when deciding which treatment to offer a patient. If there is no response to the first treatment option, one of the other treatments should be tried. Patients with a pure motor CIDP may deteriorate after corticosteroid treatment.

Some patients do not respond or become refractory or intolerant to these conventional treatments. Those who become unresponsive to therapy should be checked again for the appearance of a monoclonal protein or other signs of malignancy. Over the years, small non-randomized studies have reported possible beneficial effects of various immunosuppressive agents. A Cochrane review concluded that currently there is insufficient evidence to decide whether these immunosuppressive drugs are beneficial in CIDP. When giving immunosuppressive drugs, one should be aware that some might even cause demyelinating disease. It is difficult to prove beneficial effects of these newer treatments since they have only been used in small groups of patients, who are refractory to other treatments, and often in combination with other treatments. CIDP patients can deteriorate during or after infections or improve spontaneously, making it more difficult to judge treatment efficacy. Various treatments for CIDP are described such as azathioprine, ciclosporin, cyclophosphamide, interferons, methotrexate, mycophenolate mofetil, rituximab and etanercept. An overview of these newer treatments, their mode of action, adverse effects and potential place in the spectrum of treatments for CIDP based on previous reports and their level of evidence is given.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. European Federation of Neurological Societies/Peripheral Nerve Society. Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005 Sep; 10(3): 220–8

    Article  Google Scholar 

  2. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991 May; 41(5): 617–8

    Article  Google Scholar 

  3. Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999 May; 66(5): 677–80

    Article  PubMed  CAS  Google Scholar 

  4. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999 Dec; 46(6): 910–3

    Article  PubMed  CAS  Google Scholar 

  5. Koller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005 Mar 31; 352(13): 1343–56

    Article  PubMed  Google Scholar 

  6. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27 Suppl.: S21–4

    Article  PubMed  Google Scholar 

  7. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological study of 92 cases. Brain 1987 Dec; 110(Pt6): 1617–30

    Article  PubMed  Google Scholar 

  8. Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology 2005 Jul 12; 65(1): 138–40

    Article  PubMed  Google Scholar 

  9. van Doorn PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2005 Jun; 10(2): 113–27

    Article  PubMed  Google Scholar 

  10. van Doorn PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990 Feb; 40(2): 209–12

    Article  PubMed  Google Scholar 

  11. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996 Aug; 119(Pt 4): 1067–77

    Article  PubMed  Google Scholar 

  12. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001 Feb 27; 56(4): 445–9

    Article  PubMed  CAS  Google Scholar 

  13. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008 Feb; 7(2): 136–44

    Article  PubMed  CAS  Google Scholar 

  14. Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986 Feb 20; 314(8): 461–5

    Article  PubMed  CAS  Google Scholar 

  15. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996 Aug; 119(Pt 4): 1055–66

    Article  PubMed  Google Scholar 

  16. Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982 Feb; 11(2): 136–41

    Article  PubMed  CAS  Google Scholar 

  17. Mehndiratta MM, Singh AC. Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy. Curr Allergy Asthma Rep 2007 Jul; 7(4): 274–9

    Article  PubMed  CAS  Google Scholar 

  18. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002 Dec 24; 59 (12 Suppl. 6): S13–21

    Article  PubMed  CAS  Google Scholar 

  19. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997 Feb; 48(2): 321–8

    Article  PubMed  CAS  Google Scholar 

  20. Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995 Apr; 118(Pt 2): 359–68

    Article  PubMed  Google Scholar 

  21. Ropper AH. Chronic demyelinating polyneuropathy: improvement after sepsis. Neurology 1996 Mar; 46(3): 848–50

    PubMed  CAS  Google Scholar 

  22. Meyer zu Horste G, Hartung HP, Kieseier BC. From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract 2007 Apr; 3(4): 198–211

    Article  CAS  Google Scholar 

  23. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003; (1): CD003280

  24. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; (1): CD001797

  25. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; (1): CD002062

  26. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; (3): CD003906

  27. Echaniz-Laguna A, Battaglia F, Ellero B, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 2004 Oct; 30(4): 501–4

    Article  PubMed  Google Scholar 

  28. De Sousa EA, Brannagan III TH. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2006 Mar; 8(2): 91–103

    Article  PubMed  Google Scholar 

  29. Koski CL. Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002 Dec 24; 59 (12 Suppl. 6): S22–7

    Article  PubMed  CAS  Google Scholar 

  30. Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006 Jun; 77(6): 800–2

    Article  PubMed  CAS  Google Scholar 

  31. Thompson N, Choudhary P, Hughes RA, et al. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996 Mar; 243(3): 280–5

    Article  PubMed  CAS  Google Scholar 

  32. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993 Jan; 56(1): 36–9

    Article  PubMed  CAS  Google Scholar 

  33. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001 Aug; 50(2): 195–201

    Article  PubMed  CAS  Google Scholar 

  34. van Doorn PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: clinical and laboratory characteristics associated with improvement. Arch Neurol 1991 Feb; 48(2): 217–20

    Article  PubMed  Google Scholar 

  35. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004 May 19; 291(19): 2367–75

    Article  PubMed  CAS  Google Scholar 

  36. Ropper AH. Current treatments for CIDP. Neurology 2003 Apr 1; 60 (8 Suppl. 3): S16–22

    Article  PubMed  CAS  Google Scholar 

  37. Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 2008 Jun; 21(3): 358–65

    Article  PubMed  CAS  Google Scholar 

  38. Molenaar DS, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997 Apr; 62(4): 388–90

    Article  PubMed  CAS  Google Scholar 

  39. Eftimov F, van Schaik IN. Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy. Expert Opin Biol Ther 2008 May; 8(5): 643–55

    Article  PubMed  CAS  Google Scholar 

  40. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994 Jul; 57(7): 778–83

    Article  PubMed  CAS  Google Scholar 

  41. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994 Dec; 36(6): 838–45

    Article  PubMed  CAS  Google Scholar 

  42. van Schaik IN, Winer JB, de Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002 Dec; 1(8): 491–8

    Article  PubMed  Google Scholar 

  43. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003 Nov; 10(6): 687–94

    Article  PubMed  Google Scholar 

  44. Briellmann RS, Nydegger UE, Sturzenegger M, et al. Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins. Eur Neurol 1998; 39(3): 190–1

    PubMed  CAS  Google Scholar 

  45. Berger AR, Herskovitz S, Scelsa S. The restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 1995 Aug; 45(8): 1628–9

    Article  PubMed  CAS  Google Scholar 

  46. Walk D, Li LY, Parry GJ, et al. Rapid resolution of quadriplegic CIDP by combined plasmapheresis and IVIg. Neurology 2004 Jan 13; 62(1): 155–6

    Article  PubMed  Google Scholar 

  47. Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994 Mar; 14(2): 90–7

    Article  PubMed  CAS  Google Scholar 

  48. Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008 Mar; 37(3): 406–9

    Article  PubMed  CAS  Google Scholar 

  49. Magy L. Subcutaneous injections of polyvalent immunoglobulins as a maintenance therapy for intravenous immunoglobulin-responsive patients with chronic inflammatory demyelinating polyneuropathy [abstract]. J Peripher Nerv Syst 2008 Jun; 13(2): 176

    Google Scholar 

  50. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005 Feb; 62(2): 249–54

    Article  PubMed  Google Scholar 

  51. Nobile-Orazio E. A randomized controlled trial on the tolerability and efficacy of prolonged treatment with high-dose intravenous immunoglobulins (IVIG) or intravenous methylprednisolone (IVMP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (PIM-C trial): study design and progress report [abstract]. J Peripher Nerv Syst 2008 Jun; 13(2): 178

    Google Scholar 

  52. Dyck PJ, O’Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985 Aug; 35(8): 1173–6

    Article  PubMed  CAS  Google Scholar 

  53. Pentland B, Adams GG, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982 Oct; 45(10): 866–9

    Article  PubMed  CAS  Google Scholar 

  54. Cendrowski W. Treatment of polyneuropathy with azathioprine and adrenal steroids. Acta Med Pol 1977; 18(2): 147–56

    PubMed  CAS  Google Scholar 

  55. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981; 9 Suppl.: 134–45

    Article  PubMed  Google Scholar 

  56. Walker GL. Progressive polyradiculoneuropathy: treatment with azathioprine. Aust N Z J Med 1979 Apr; 9(2): 184–7

    Article  PubMed  CAS  Google Scholar 

  57. Pentland B. Azathioprine in chronic relapsing idiopathic polyneuropathy. Postgrad Med J 1980 Oct; 56(660): 734–5

    Article  PubMed  CAS  Google Scholar 

  58. Heathfield K, Dallos V. Treatment of polyneuropathy with azathioprine. Lancet 1970 Nov 14; 2(7681): 1030–1

    Article  PubMed  CAS  Google Scholar 

  59. Barnett MH, Pollard JD, Davies L, et al. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998 Apr; 21(4): 454–60

    Article  PubMed  CAS  Google Scholar 

  60. Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2004 Sep 15; 224(1–2): 29–35

    Article  PubMed  CAS  Google Scholar 

  61. Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996 Feb; 60(2): 185–7

    Article  PubMed  CAS  Google Scholar 

  62. Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990 Apr; 53(4): 327–30

    Article  PubMed  CAS  Google Scholar 

  63. Odaka M, Tatsumoto M, Susuki K, et al. Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005 Aug; 76(8): 1115–20

    Article  PubMed  CAS  Google Scholar 

  64. Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol 2005 Nov; 33(5): 368–72

    Article  PubMed  Google Scholar 

  65. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001 Jan 9; 56(1): 94–6

    Article  PubMed  CAS  Google Scholar 

  66. Vermersch P, Stojkovic T, de Seze J. Mycophenolate mofetil and neurological diseases. Lupus 2005; 14 Suppl. 1: s42–5

    Article  PubMed  CAS  Google Scholar 

  67. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004 Aug 24; 63(4): 715–7

    Article  PubMed  CAS  Google Scholar 

  68. Benedetti L, Grandis M, Nobbio L, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004 May; 29(5): 748–9

    Article  PubMed  Google Scholar 

  69. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001 Apr 1; 185(2): 119–22

    Article  PubMed  CAS  Google Scholar 

  70. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002 Nov; 9(6): 683–5

    Article  PubMed  CAS  Google Scholar 

  71. Brannagan III TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002 Jun 25; 58(12): 1856–8

    Article  PubMed  CAS  Google Scholar 

  72. Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998 Dec; 51(6): 1735–8

    Article  PubMed  CAS  Google Scholar 

  73. Gladstone DE, Prestrud AA, Brannagan III TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005 Mar; 10(1): 11–6

    Article  PubMed  CAS  Google Scholar 

  74. Gladstone DE, Golightly MG, Brannagan III TH. High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 2007 Oct; 190(1–2): 121–6

    Article  PubMed  CAS  Google Scholar 

  75. Fowler H, Vulpe M, Marks G, et al. Recovery from chronic progressive polyneuropathy after treatment with plasma exchange and cyclophosphamide [letter]. Lancet 1979 Dec 1; II(8153): 1193

    Article  Google Scholar 

  76. Fialho D, Chan YC, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006 Apr; 77(4): 544–7

    Article  PubMed  CAS  Google Scholar 

  77. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009 Feb; 8(2): 158–64

    Article  CAS  Google Scholar 

  78. Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998 Jan; 50(1): 84–7

    Article  PubMed  CAS  Google Scholar 

  79. Gorson KC, Allam G, Simovic D, et al. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997 Mar; 48(3): 777–80

    Article  PubMed  CAS  Google Scholar 

  80. Pavesi G, Cattaneo L, Marbini A, et al. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002 Jun; 249(6): 777–9

    Article  PubMed  Google Scholar 

  81. Sabatelli M, Mignogna T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995 May; 58(5): 638–9

    Article  PubMed  CAS  Google Scholar 

  82. Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999 Jul 13; 53(1): 57–61

    Article  PubMed  CAS  Google Scholar 

  83. Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003 Apr 1; 60 (8 Suppl. 3): S23–8

    Article  PubMed  CAS  Google Scholar 

  84. Cocco E, Mamusa E, Carboni N, et al. Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon beta 1B. J Neurol 2005 Nov; 252(11): 1420–2

    Article  PubMed  Google Scholar 

  85. Martina IS, van Doorn PA, Schmitz PI, et al. Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999 Feb; 66(2): 197–201

    Article  PubMed  CAS  Google Scholar 

  86. Choudhary PP, Thompson N, Hughes RA. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995 Mar; 242(4): 252–3

    Article  PubMed  CAS  Google Scholar 

  87. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999 Oct 12; 53(6): 1364–5

    Article  PubMed  CAS  Google Scholar 

  88. Gorson KC, Hughes R, Cros D, et. al. Efficacy of interferon beta-1a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [abstract no. P07.101]. American Academy Neurology, 60th Annual meeting; 2008 Apr 17; Chicago (IL)

  89. Pirko I, Kuntz NL, Patterson M, et al. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Neurology 2003 May 27; 60(10): 1697–9

    Article  PubMed  CAS  Google Scholar 

  90. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000 Mar; 23(3): 433–5

    Article  PubMed  CAS  Google Scholar 

  91. Marzo ME, Tintore M, Fabregues O, et al. Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha [letter]. J Neurol Neurosurg Psychiatry 1998 Oct; 65(4): 604

    Article  PubMed  CAS  Google Scholar 

  92. Harada H, Ohkoshi N, Fujita Y, et al. Clinical improvement following interferon-alpha alone as an initial treatment in CIDP. Muscle Nerve 2000 Feb; 23(2): 295–6

    Article  PubMed  CAS  Google Scholar 

  93. Levine TD, Pestronk A. IgM antibody-related poly-neuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999 May 12; 52(8): 1701–4

    Article  PubMed  CAS  Google Scholar 

  94. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003 Apr; 74(4): 485–9

    Article  PubMed  CAS  Google Scholar 

  95. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006 Mar 14; 66(5): 742–4

    Article  PubMed  CAS  Google Scholar 

  96. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003 May; 27(5): 611–5

    Article  PubMed  CAS  Google Scholar 

  97. Knecht H, Baumberger M, Tobon A, et al. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004 Aug 24; 63(4): 730–2

    Article  PubMed  Google Scholar 

  98. Gono T, Matsuda M, Shimojima Y, et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 2006 Jul; 13(6): 683–7

    Article  PubMed  CAS  Google Scholar 

  99. Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007 Jan; 35(1): 66–9

    Article  PubMed  CAS  Google Scholar 

  100. Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP [letter]. Eur J Neurol 2004 Nov; 11(11): 788

    Article  PubMed  CAS  Google Scholar 

  101. Wilson JR, Conwit RA, Eidelman BH, et al. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve 1994 May; 17(5): 528–32

    Article  PubMed  CAS  Google Scholar 

  102. Ahlmen J, Andersen O, Hallgren G, et al. Positive effects of tacrolimus in a case of CIDP [letter]. Transplant Proc 1998 Dec; 30(8): 4194

    Article  PubMed  CAS  Google Scholar 

  103. Bronster DJ, Yonover P, Stein J, et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. Transplantation 1995 Apr 15; 59(7): 1066–8

    Article  PubMed  CAS  Google Scholar 

  104. Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003 Jun 15; 21(1–2): 19–21

    Article  CAS  Google Scholar 

  105. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001 Nov 27; 57(10): 1885–8

    Article  PubMed  CAS  Google Scholar 

  106. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008 May; 131(Pt 5): 1197–208

    PubMed  Google Scholar 

  107. Davis J. Eculizumab. Am J Health Syst Pharm 2008 Sep 1; 65(17): 1609–15

    Article  PubMed  CAS  Google Scholar 

  108. Maramattom BV, Wijdicks EF. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology 2004 Nov 23; 63(10): 1958–9

    Article  PubMed  CAS  Google Scholar 

  109. Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology 2007 Jun 5; 68(23): 2039–40

    Article  PubMed  Google Scholar 

  110. Bilodeau M, Hassoun Z, Brunet D. Demyelinating sensorimotor polyneuropathy associated with the use of sirolimus: a case report. Transplant Proc 2008 Jun; 40(5): 1545–7

    Article  PubMed  CAS  Google Scholar 

  111. Vermeulen M, van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002 Jan; 72(1): 127–8

    Article  PubMed  CAS  Google Scholar 

  112. Vermeulen M, van Oers MH. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation [letter]. J Neurol Neurosurg Psychiatry 2007 Oct; 78(10): 1154

    Article  PubMed  CAS  Google Scholar 

  113. Oyama Y, Sufit R, Loh Y, et al. Nonmyeloablative autologous hematopoietic stem celltransplantation for refractory CIDP. Neurology 2007 Oct 30; 69(18): 1802–3

    Article  PubMed  CAS  Google Scholar 

  114. Remenyi P, Masszi T, Borbenyi Z, et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007 Aug; 14(8): e1–2

    Article  PubMed  CAS  Google Scholar 

  115. Nagashima T, Sato F, Chuma T, et al. Chronic demyelinating polyneuropathy in graft-versus-host disease following allogeneic bone marrow transplantation. Neuropathology 2002 Mar; 22(1): 1–8

    PubMed  Google Scholar 

  116. Lorenzoni PJ, Scola RH, Carsten AL, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: case report. Arq Neuropsiquiatr 2007 Sep; 65(3A): 700–4

    Article  PubMed  Google Scholar 

  117. Openshaw H, Hinton DR, Slatkin NE, et al. Exacerbation of inflammatory demyelinating polyneuropathy after bone marrow transplantation. Bone Marrow Transplant 1991 May; 7(5): 411–4

    PubMed  CAS  Google Scholar 

  118. Peters G, Larner AJ. Chronic inflammatory demyelinating polyneuropathy after autologous peripheral blood stem cell transplantation. J Peripher Nerv Syst 2005 Dec; 10(4): 384–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The Department of Neurology, Erasmus MC, Rotterdam, has received a research grant from Baxter. Dr van Doorn has received a consultancy fee from Talecris as a member of the IGIV CIDP Efficacy (ICE) trial.

Author information

Authors and Affiliations

  1. Erasmus MC, Room H 673, s-Gravendijkwal 230, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

    Krista Kuitwaard & Pieter A. van Doorn

Authors
  1. Krista Kuitwaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pieter A. van Doorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Krista Kuitwaard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuitwaard, K., van Doorn, P.A. Newer Therapeutic Options for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Drugs 69, 987–1001 (2009). https://doi.org/10.2165/00003495-200969080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969080-00004

Keywords

Search

Navigation